- |||||||||| Zeposia (ozanimod) / BMS, cisplatin / Generic mfg.
Journal: Contribution of S1pr1 -featured astrocyte subpopulation to cisplatin-induced neuropathic pain. (Pubmed Central) - Apr 16, 2025
These data not only highlight FGFR3 as one of the astrocytic targets of S1PR1 but raise the possibility that S1PR1-induced engagement of Wnt signaling in S1pr1 high astrocytes may contribute to CIPN. Overall, our results provide a comprehensive mapping of cellular and molecular changes engaged in cisplatin-induced neuropathic pain and decipher novel S1PR1-based mechanisms of action.
- |||||||||| Review, Journal: Drug- and Vaccine-Induced Cutaneous T-Cell Lymphoma: A Systematic Review of the Literature. (Pubmed Central) - Apr 14, 2025
Infliximab (n?=?6) and etanercept (n?=?5) were the most commonly reported biologics...Six patients passed away after being diagnosed with CTCL: two because of CTCL recurrence and four because of other complications. It is important recognizing CTCL as a possible, although rare, adverse effect of certain drugs and vaccines, and taking a history of vaccinations, especially COVID-19 vaccines, and immunosuppressive drugs such as fingolimod, TNF-a inhibitors, and methotrexate.
- |||||||||| fingolimod / Generic mfg.
Review, Journal: The potential capacities of FTY720: Novel therapeutic functions, targets, and mechanisms against diseases. (Pubmed Central) - Apr 12, 2025
Additionally, it summarizes FTY720's derivation and development process, the characterization and mechanism of the structure of FTY720-P bound to S1PRs, the clinical safety profile, future challenges, and potential strategies to address them. These insights aim to guide future research and applications of FTY720, maximizing its therapeutic potential.
- |||||||||| LX 2931 / Lexicon Pharma
Preclinical, Journal: Dual action of sphingosine 1-phosphate pathway in in vitro models of global cerebral ischemia. (Pubmed Central) - Apr 11, 2025
In the same model we investigated the effect of the inhibitor of S1P lyase (SPL), LX2931, the selective antagonists of S1P2, JTE-013, and S1P3, CAY10444, quantifying the cell death in the CA1 region by propidium iodide fluorescence, and morphological and tissue organization alterations by immunohistochemistry and confocal microscopy...Our results reveal a dual role of S1P pathway in brain ischemia: intracellular S1P, degraded via SPL, appears to be beneficial whereas signaling via S1P2 and S1P3 is detrimental to the disease. These findings support the notion that SPL, S1P2 and S1P3 are promising therapeutic targets in brain ischemia.
- |||||||||| S1PR agonist / Boehringer Ingelheim
Journal: Intracellular Sphingosine-1-Phosphate Induces Lipolysis Through Direct Activation of Protein Kinase C Zeta. (Pubmed Central) - Apr 7, 2025
Here, we have concentrated on the latter, as 10-50??M S1P potently increased lipolysis in differentiated 3T3-L1 adipocytes, whereas S1P concentrations sufficient to activate S1P receptors (S1PRs; 0.1-1??M) or S1PR agonists had no effect...PKC zeta phosphorylation and activity, as well as HSL Ser660 phosphorylation, were increased in gWAT of DOP-treated mice. This study assigns lipolysis as the first physiological function of PKC zeta activation by S1P and identifies an exclusive adipocyte-specific aspect of S1P function in obesity.
- |||||||||| Zeposia (ozanimod) / BMS
Journal: Asymmetric Synthesis of N-Hydroxyethyl Amino Indane Derivatives Catalyzed by an Engineered Imine Reductase. (Pubmed Central) - Apr 7, 2025
In this study, an imine reductase mutant (IR262-F185E/F229L) was identified with high enantioselectivity toward various N-hydroxyethyl imino derivatives. Furthermore, a continuous fed-batch strategy was designed to avoid the hydrolysis of imines, and up to 200 mM 1-((2-hydroxyethyl)imino)-2,3-dihydro-1H-indene-4-carbonitrile could be completely converted into (S)-1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-indene-4-carbonitrile in 70% isolated yield and >99% ee, demonstrating a great potential for the synthesis of the ozanimod intermediate in industrial applications.
- |||||||||| Journal: Recent advances in epidemiology, pathogenesis, diagnosis, and treatment of inflammatory bowel disease: Insights from the past two years. (Pubmed Central) - Apr 6, 2025
Despite these advancements, approximately one-third of patients remain primary non-responders to the initial treatment, and half eventually lose response over time. Precision medicine integrating multi-omics data, advanced combination therapy, and complementary approaches, including stem cell transplantation, psychological therapies, neuromodulation, and gut microbiome modulation therapy, may offer solutions to break through the therapeutic ceiling.
- |||||||||| Mayzent (siponimod) / Novartis, fingolimod / Generic mfg.
Journal, Adverse events: Identifying cardiovascular toxicity associated with sphingosine 1-phosphate receptor modulators: A case-control study based on the FDA adverse event reporting system. (Pubmed Central) - Apr 5, 2025
Precision medicine integrating multi-omics data, advanced combination therapy, and complementary approaches, including stem cell transplantation, psychological therapies, neuromodulation, and gut microbiome modulation therapy, may offer solutions to break through the therapeutic ceiling. In this study, signals of bradyarrhythmias, hypertension, QT interval prolongation, central nervous system ischemia, tachyarrhythmias, and ischaemic heart disease were significant with one or more S1PR modulators, which warrant clinical attention and ongoing monitoring.
- |||||||||| fingolimod / Generic mfg.
Journal: Early and active treatment with fingolimod (Pubmed Central) - Apr 2, 2025
Fingolimod offers better compliance and significantly improves patients' quality of life compared to injection therapies especially in pediatric population, reducing injection associated anxiety and risk of discontinuation. It appears to be safe and well tolerated and may be used as first line treatment in the highly active and aggressive disease course of pediatric onset multiple sclerosis.
- |||||||||| Journal: Recommendations for essential medicines for multiple sclerosis in low-resource settings. (Pubmed Central) - Apr 1, 2025
It appears to be safe and well tolerated and may be used as first line treatment in the highly active and aggressive disease course of pediatric onset multiple sclerosis. Recommendations for the minimum essential DMTs for MS in low-resource settings were developed based on robust consideration of evidence and relevant context.
- |||||||||| Tysabri (natalizumab) / Biogen, Royalty, Ocrevus (ocrelizumab) / Roche, Rituxan (rituximab) / Roche
Journal: Reevaluation of the gastrointestinal methanogenic archaeome in multiple sclerosis and its association with treatment. (Pubmed Central) - Apr 1, 2025
Most MS patients were female (80/115), aged 25-72 years (median: 44.5), and 70% were undergoing treatment, including dimethyl fumarate (n = 21), fingolimod (n = 20), glatiramer acetate (n = 14), interferon (n = 18), natalizumab (n = 6), or ocrelizumab/rituximab (n = 1)...By focusing on methanogens, we aim to uncover novel insights into their role in MS, potentially revealing new biomarkers or therapeutic targets. This research is crucial for enhancing our understanding of the gut microbiome's impact on MS and improving patient management.
- |||||||||| Mayzent (siponimod) / Novartis
Journal: Siponimod inhibits microglial inflammasome activation. (Pubmed Central) - Mar 28, 2025
Our data indicate that siponimod achieves its anti-inflammatory effects by inhibiting inflammasome activation in microglia via S1P1 antagonism. This process is inferred to play a crucial role in mitigating the secondary progression of multiple sclerosis, where microglial activation in the gray matter is considered a key pathological factor.
- |||||||||| Review, Journal: Therapeutic Advances in Pediatric Multiple Sclerosis. (Pubmed Central) - Mar 28, 2025
We will also review the safety and efficacy of different monoclonal antibodies that are commonly prescribed for multiple sclerosis. We will then examine induction versus escalation treatment strategies and conclude with discussions on treatment considerations in POMS patients.
- |||||||||| Ocrevus (ocrelizumab) / Roche
Journal: Extensive T-Cell Profiling Following SARS-CoV-2 mRNA Vaccination in Multiple Sclerosis Patients Treated with DMTs. (Pubmed Central) - Mar 27, 2025
While humoral immune response was impaired in pwMS during ocrelizumab and fingolimod treatment, there was evidence of a compensatory upregulation of subpopulations of SARS-CoV-2-specific CD4+ T cells at low levels of seroconversion in pwMS. In conclusion, our results provide important insights into the mechanisms of the adaptive immune response in pwMS following SARS-CoV-2 mRNA vaccination.
- |||||||||| fingolimod / Generic mfg.
Journal: Effects of systemic fingolimod treatment on anterior segment parameters and tear film functions. (Pubmed Central) - Mar 27, 2025
The mean TBUT was significantly higher at the six-month visit compared to baseline and the one-month visit (p0-6 < 0.001, p1-6 < 0.001), but there was no statistically significant difference between baseline and month 1 (p0-1 = 0.419). Systemic use of fingolimod may increase Schirmer I test and TBUT values in MS patients without altering other anterior segment parameters within 6?months.
- |||||||||| Review, Journal: Small Molecules in the Treatment of Acute Severe Ulcerative Colitis: A Review of Current Evidence. (Pubmed Central) - Mar 27, 2025
Conversely, it is necessary to investigate whether infliximab can be effectively replaced or surpassed by other approved biological agents and small molecules as first-line therapy after steroid resistance. This review aims to summarise the available evidence on small molecules, specifically Janus kinase inhibitors and sphingosine-1-phosphate receptor modulators.
- |||||||||| fingolimod / Generic mfg.
Journal: Pre-existing parasympathetic dominance seems to cause persistent heart rate slowing after 6 (Pubmed Central) - Mar 26, 2025
This review aims to summarise the available evidence on small molecules, specifically Janus kinase inhibitors and sphingosine-1-phosphate receptor modulators. Our patients with prolonged HR slowing upon fingolimod initiation could not downregulate cardiovagal modulation upon standing up even before fingolimod initiation, and 6
- |||||||||| Zeposia (ozanimod) / BMS
Journal: Ozanimod-associated macular edema. (Pubmed Central) - Mar 26, 2025
Our patients with prolonged HR slowing upon fingolimod initiation could not downregulate cardiovagal modulation upon standing up even before fingolimod initiation, and 6 No abstract available
- |||||||||| BXQ-350 / Bexion
Development of an in-house methodology to analyze large clinical cancer biomarkers datasets (Section 47; Poster Board No: 12) - Mar 25, 2025 - Abstract #AACR2025AACR_2677;
Furthermore, such analyses can support understanding the mechanism of action and guide patient selection. The method developed allows for flexible and granular analysis of biomarkers and correlative analysis across different groups of biomarkers or individual patients and groups of patients
- |||||||||| Review, Journal: Paradigm Shift in Inflammatory Bowel Disease Management: Precision Medicine, Artificial Intelligence, and Emerging Therapies. (Pubmed Central) - Mar 17, 2025
Emerging therapies, precision medicine, and ongoing research into novel targets promise to reshape the IBD treatment landscape. As these advances continue to unfold, IBD patients can anticipate a brighter future, one marked by more effective, personalized, and accessible treatments.
- |||||||||| Remicade (infliximab) / J&J, Zeposia (ozanimod) / BMS, Rinvoq (upadacitinib) / AbbVie
Journal, Real-world evidence: Real-world prevalence of potential drug-drug interactions associated with oral advanced therapies indicated for ulcerative colitis. (Pubmed Central) - Mar 14, 2025
For JAK inhibitors, these were COVID-19 vaccines (30.7% and 31.4%), infliximab (8.5% and 20.2%), fluconazole (6.1% and 6.8%), and azathioprine (5.5% and 13.0%)...Comorbidities and polypharmacy among patients with UC pose a high risk of DDIs for oral advanced therapies, and required pre-treatment clinical assessments can be complicated. This justifies a thorough review of patient profiles for prescribers considering novel treatment options.
- |||||||||| Journal, Adverse events, Real-world evidence: Herpes Zoster Infections With Multiple Sclerosis Disease-Modifying Therapies: A Real-World Pharmacovigilance Study. (Pubmed Central) - Mar 14, 2025
We queried the Food and Drug Administration Adverse Event Reporting System (FAERS) and OpenVigil 2.1 for reports of HZ involving immunosuppressive MS DMTs (ocrelizumab [OCR], ofatumumab [OFT], rituximab [RTX], natalizumab [NTZ], alemtuzumab, dimethyl fumarate and diroximel fumarate [DRF], fingolimod [FING], siponimod [SIP], ozanimod [OZ], mitoxantrone [MITO], cladribine [CLAD], and teriflunomide [TERF]) and calculated reporting odds ratios and their 95% CIs...Immunosuppressive MS DMTs are associated with greater HZ reporting in the FAERS. These findings emphasize the importance of pre-DMT HZ vaccination because of avoidable HZ infections.
- |||||||||| fingolimod / Generic mfg.
Journal: Protection conferred by mucosal novel bivalent Klebsiella pneumoniae vaccine immunization associates with presence of lung CD4+ TRM. (Pubmed Central) - Mar 14, 2025
Transcriptomic analysis of total lung tissues from mice treated by FTY720 (S1PR1 inhibitor that blocks lymphocyte egress from secondary lymphoid structures) showed that cell activation, cytokine secretion and enhancement of the killing ability of neutrophils were related to the mechanism of protection against K. pneumoniae infection. These findings indicate that GlnH and FimA are effective candidate bivalent vaccine to fight K. pneumoniae infection.
|
